UK Launches Multi-Arm Alzheimer's Trial to Test Repurposed Diabetes and ADHD Drugs

For decades, the pharmaceutical industry has operated on the assumption that Alzheimer's disease treatments must be tested sequentially, evaluating one experimental compound at a time against a dedicated placebo group. This traditional framework often requires a decade or more to yield a single answer, leaving patients with few options as their cognitive function declines.[1][5]

A new national clinical trial launched today across the United Kingdom directly challenges that sequential model by testing multiple repurposed medications simultaneously. The AD-SMART platform trial will evaluate whether existing drugs for type 2 diabetes and attention deficit hyperactivity disorder can slow Alzheimer's progression.[1][2][8]

By comparing several active treatments against a single shared placebo group, the initiative aims to cut the time required to evaluate new therapies by more than half. The trial is led by the UK Dementia Research Institute at Imperial College London and Alzheimer's Research UK, with backing from the National Health Service.[3][4][5]

"For too long, Alzheimer's research has moved at the pace of one drug, one trial, one answer, sometimes taking a decade or more before we know if we've found something that works," said Professor Paresh Malhotra, the trial's chief investigator. "We are applying advances from cancer and other conditions to accelerate testing."[2][4][5]

Repurposing existing medications

The trial's first phase will evaluate metformin, a widely prescribed blood glucose-lowering medication for type 2 diabetes, alongside atomoxetine, a selective noradrenaline reuptake inhibitor used to treat ADHD. Both medications have demonstrated potential in early laboratory studies to reduce brain inflammation, a key driver of neurodegeneration.[1][2][8]

Metformin has increasingly drawn interest from neurology researchers due to its ability to modulate metabolic pathways and potentially clear toxic protein buildups in the brain. Atomoxetine, meanwhile, enhances noradrenaline signaling, which researchers believe could help protect vulnerable neural circuits from the inflammatory damage characteristic of Alzheimer's.[1][8]

Because these drugs are already approved by regulators and have established safety profiles, any successful candidate could be deployed to memory clinics rapidly. Researchers will monitor whether the medications can preserve memory, maintain thinking skills, and protect overall quality of life as the disease advances.[1][3]

Alzheimer's disease currently affects approximately 600,000 people in the UK alone, and there are currently no treatments available through the NHS that can halt or reverse the underlying pathology. Existing standard-of-care medications are limited to temporarily managing symptoms rather than altering the disease trajectory.[1][5]

The trial aims to recruit 1,200 participants across the UK, encompassing individuals in both early and advanced stages of Alzheimer's disease. Unlike traditional trials that often exclude patients with complex medical histories, AD-SMART is designed to reflect the real-world population seen in everyday NHS memory clinics.[3][8]

The multi-arm platform model

Participants will be permitted to continue their standard Alzheimer's treatments while enrolled in the study. This pragmatic approach allows researchers to evaluate how the repurposed diabetes and ADHD medications perform alongside routine care, rather than in an artificial clinical vacuum.[3][8]

The systematic multi-arm adaptive randomized trial design represents a structural shift in how neurodegenerative research is conducted. If a specific medication fails to demonstrate clear clinical benefit during regular interim data checks, it is rapidly dropped from the protocol and replaced with a new candidate.[1][2][5]

This adaptive structure ensures that fewer participants are exposed to ineffective treatments over long periods, addressing a major ethical concern in dementia research. It also maximizes the statistical power of the shared placebo group, significantly reducing the total number of patients required to reach definitive conclusions.[3][4]

"The way AD-SMART is set up means we're testing several treatments at the same time, and those that don't show promise can be quickly stopped," Malhotra explained. "Then we can start testing something else. That's the best way to get effective treatments to patients as quickly as we can."[3][4][5]

The platform model has already proven successful in accelerating research for other complex conditions. A similar UK trial for motor neuron disease, MND-SMART, definitively concluded that its first round of tested drugs was ineffective in just over three years—a process that would conventionally take at least eight.[2]

Expanding the research pipeline

While the trial begins with metformin and atomoxetine, the infrastructure is designed to continuously integrate new experimental therapies as they emerge from laboratory research. An international panel of experts, alongside individuals with lived experience of Alzheimer's, will select future candidates based on preclinical evidence.[8]

The initiative is supported by a coalition of major research bodies, including the Medical Research Council, Health Data Research UK, and the National Institute for Health and Care Research. Ongoing funding has been committed by the UK government, reflecting a national push to prioritize dementia research and build permanent trial infrastructure.[2][4][5]

"AD-SMART will help to uncover new treatments faster by exploring how existing drugs might be used to treat dementia," said UK Science Minister Chris McDonald. He noted that the initiative provides hope for improving patients' quality of life while reducing the immense socioeconomic burden of the disease.[2][5]

The first definitive results from the metformin and atomoxetine arms are expected by 2030. Until then, the trial infrastructure will continue expanding across more than 30 planned NHS sites, establishing a permanent testing network that remains active even as individual drug candidates change.[2][3]

Dr. Sheona Scales, Director of Research at Alzheimer's Research UK, emphasized the urgency of the new approach. "For people living with Alzheimer's disease, time is precious," she said. "We urgently need more treatment options that can help people live better for longer and stay connected to the people they love."[5]